[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 45 of about 45
1. Gupta D, Sharma A, Raina V, Bakhshi S, Mohanti BK: Primary testicular non-Hodgkin lymphoma: a single institution experience from India. Indian J Cancer; 2009 Jan-Mar;46(1):46-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular non-Hodgkin lymphoma: a single institution experience from India.
  • BACKGROUND: Primary testicular non-Hodgkin lymphoma (NHL) is an uncommon extra nodal presentation, constituting 1% of all NHL.
  • Median age at time of presentation is 60 years.
  • There is not enough data on use of monoclonal antibody (Rituximab) in testicular NHL.
  • METHODS: We screened approximately eight hundred and fifty NHL cases registered from January 2002 to May 2008 and found six primary testicular NHL patients.
  • These six cases were analyzed for baseline clinical features, investigations, staging, treatment and outcome variables.
  • All patients had testicular swelling and abdominal lymphadenopathy.
  • All patients were treated with anthracycline based combination chemotherapy and CNS prophylaxis after local therapy except one pediatric patient who did not receive any local therapy.
  • Four patients completed therapy and are on follow up while two patients having extensive disease with poor performance status died of neutropenic sepsis after 1-2 cycles of chemotherapy.
  • CONCLUSION: Primary testicular NHL is an uncommon entity and with current combined modality treatment and CNS prophylaxis, the outcome may be as good as nodal NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282566.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


2. Kulkarni KP, Marwaha RK, Trehan A, Bansal D: Testicular relapse in childhood acute lymphoblastic leukemia: the challenges and lessons. Indian J Cancer; 2010 Apr-Jun;47(2):134-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular relapse in childhood acute lymphoblastic leukemia: the challenges and lessons.
  • Although testicular relapse is rare with modern risk-adapted treatment protocols, earlier, the testes were a frequently encountered site of relapse and were designated as "drug sanctuaries".
  • PURPOSE: This descriptive study was designed to assess the pattern of testicular relapse and to identify high-risk factors.
  • RESULTS: Testicular relapse was documented in 30 boys.
  • Twelve of the 30 boys with testicular relapse were treated with testicular irradiation, reinduction and maintenance therapy.
  • CONCLUSION: Testicular relapse, which depends on the therapy administered, may manifest several months/years after completion of treatment.
  • The high incidence of testicular relapse in our series implicates the need of revaluation of our protocol and incorporation of high/intermediate dose methotrexate therapy upfront.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Asparaginase / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Cranial Irradiation. Humans. Infant. Male. Methotrexate / administration & dosage. Prednisolone / administration & dosage. Survival Rate. Treatment Outcome. Vincristine / administration & dosage


3. Abd El-Aal HH, Habib EE, Mishrif MM: Rhabdomyosarcoma: the experience of the pediatric unit of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) (from January 1992 to January 2001). J Egypt Natl Canc Inst; 2006 Mar;18(1):51-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma: the experience of the pediatric unit of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) (from January 1992 to January 2001).
  • Our present study is a retrospective analysis of the treatment results of new rhabdomyosarcoma pediatric patients who had attended the pediatric unit clinic of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) from January 1992 to January 2001).
  • PATIENTS AND METHODS: Fifty-five new cases of pediatric rhabdomyosarcoma attended the pediatric unit outpatient clinic of (NEMROCK) from the period of January 1992 until January 2001.
  • Stage I, II orbital and stage I para-testicular embryonal rhabdomyosarcomas received 32 weeks of vincristine and actinomycin- D (vincristine 1.5 mg/m2 weekly, actinomycin-D 0.015 mg/Kg/day day 1 to day 5).
  • Other pathologies, sites and stages received 52 weeks of chemotherapy.
  • Chemotherapy regimens included VAC (vincristine 1.5 mg/m2 weekly, actinomycin-D 0.015 mg/Kg/day day 1 to day 5 and endoxan 2.2 gm/m2 I.V with mesna every 21 days), VAI (vincristine, actinomycin-D and ifosfamide 1.8 gm/m2 I.V day 1 to day 5 with mesna) or VIE (vincristine, ifosfamide and vepesid 100 mg/m2 I.V day 1 to day 5) [11,12].
  • Stages I and II received conventional fractionation radiotherapy 4140 cGy on week 13, stages III and IV received conventional fractionation radiation therapy 5040 cGy also, on week 13.
  • The radiation volume included the tumor bed with a 2 cm safety margin at least.
  • Relapsing cases received palliative radiation therapy and chemotherapy (cisplatinum I.V 100 mg/m2 divided over 2 days and vepesid 100 mg/m2 I.V day 1 to day 3 to be recycled every 21 days).
  • Overall survival, disease free survival, treatment response, and complications of treatment were assessed and statistically analyzed.
  • RESULTS: Fifty-five new cases of pediatric rhabdomyosarcoma attended the pediatric unit outpatient clinic of (NEMROCK) and were evaluated.
  • Pathologically, embryonal type was the commonest statistically (48/55, i.e.
  • 87.3%) compared to the alveolar type (7/55, i.e. 12.7%).
  • Concerning site of the primary tumor it was found to be highest in the head and neck (20/55, i.e.
  • CONCLUSION: Despite the advances in the therapy of rhabdomyosarcoma.
  • Nearly 30% of the pediatric cases with rhabdomyosarcoma experience progressive or relapsing disease, which has a fatal end.
  • The factors determining the 5-year survival after relapse at the time of initial diagnosis include histological subtype, and disease cluster.
  • These findings will form the basis of a multi-institutional risk adapted relapse protocol for childhood rhabdomyosarcoma patients.
  • [MeSH-major] Rhabdomyosarcoma / mortality. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Neoplasm Staging. Prognosis. Radiotherapy. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237856.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


Advertisement
4. Wessalowski R, Schneider DT, Mils O, Hannen M, Calaminus G, Engelbrecht V, Pape H, Willers R, Engert J, Harms D, Göbel U: An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Klin Padiatr; 2003 Nov-Dec;215(6):303-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors.
  • BACKGROUND: Elevated temperatures of 40 - 44 degrees C increase the actions of various anticancer drugs including N-lost derivatives, cytotoxic antibiotics and platinum analoga.
  • In clinical usage thermochemotherapy (TCH) should facilitate surgical resection and ameliorate local tumor control.
  • Among these, 24 patients had extracranial non-testicular germ cell tumors and 15 patients soft tissue or chondrosarcomas.
  • INDICATION: locoregional relapse (n = 29) or unresectable tumor after neoadjuvant chemotherapy (n = 10).
  • Among these two groups, there were ten patients with poor response or progressive disease under primary or relapse chemotherapy.
  • Tumor site: pelvis (30), abdomen (4), head and neck (2), proximal leg (2) and lumbar spine (1).
  • TCH was followed by surgical tumor resection in 28/39 patients and/or radiotherapy in 13/39 patients.
  • CONCLUSION: TCH shows substantial therapeutic efficacy and facilitates complete tumor resection in 14 out of 28 operated patients.
  • Multimodal treatment including TCH, surgical resection and/or radiotherapy leads to sustained remission in the majority of patients with locoregional tumor recurrence.
  • The therapeutic effect is most pronounced, if TCH is administered at first relapse.
  • Therefore, a more valid assessment of treatment efficacy can only be made by a matched-pair comparison in cooperation with the clinical registers.
  • [MeSH-major] Abdominal Neoplasms / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Chondrosarcoma / therapy. Cisplatin / therapeutic use. Etoposide / therapeutic use. Germinoma / therapy. Head and Neck Neoplasms / therapy. Hyperthermia, Induced. Ifosfamide / therapeutic use. Lumbar Vertebrae. Pelvic Neoplasms / therapy. Sarcoma / therapy. Soft Tissue Neoplasms / therapy. Spinal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Chi-Square Distribution. Child. Child, Preschool. Combined Modality Therapy. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Infant. Karnofsky Performance Status. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Time Factors. Treatment Outcome


5. Ye YL, Qin ZK, Zhou FJ, Han H, Liu ZW, Yu SL, Li YH, Chen ZF: [Clinical analysis of stage I pediatric testicular yolk sac tumors: a report of ten cases]. Ai Zheng; 2008 Nov;27(11):1226-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of stage I pediatric testicular yolk sac tumors: a report of ten cases].
  • BACKGROUND & OBJECTIVE: At present, pediatric testicular yolk sac tumor is hard to be diagnosed at early stage, and the treatment strategy for this disease after radical inguinal orchiectomy is uncertain.
  • This study was to summarize our experience in diagnosing and treating clinical stage I pediatric testicular yolk sac tumors.
  • METHODS: Clinical data of ten patients with clinical stage I pediatric testicular yolk sac tumors treated from July 2001 to June 2007 were analyzed.
  • RESULTS: Testicular masses with low or uneven echoes were detected by B ultrasound in 11 testes of ten patients.
  • Radical inguinal orchiectomy (RIO) was performed for all patients whereas chemotherapy was not administered preoperatively.
  • Pathology examination was used to confirm the diagnosis of yolk sac tumor.
  • One patient with vascular invasion and another one with bilateral testicular yolk sac tumor received cisplatin-based adjuvant chemotherapy.
  • The patient with bilateral testicular tumor had retroperitoneal and lung metastases at 23 months after adjuvant chemotherapy, and achieved complete remission again after salvage chemotherapy.
  • CONCLUSIONS: With the combination of B ultrasound and serum AFP level, we can assess and diagnose stage I pediatric testicular yolk sac tumor.
  • Chemotherapy is recommended to treat patients with high-risk of relapse.
  • [MeSH-major] Endodermal Sinus Tumor. Testicular Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Chemotherapy, Adjuvant. Child, Preschool. Cisplatin / therapeutic use. Etoposide / therapeutic use. Follow-Up Studies. Humans. Infant. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Neoplasm Staging. Orchiectomy / methods. Remission Induction. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / secondary. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19000459.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


6. Belasco JB, Goldwein JW, Simms S, Griffin G, D'Angio G, Lange B: Hypofractionated moderate dose radiation, intrathecal chemotherapy, and repetitive reinduction/reconsolidation systemic therapy for central nervous system relapse of acute lymphoblastic leukemia in children. Med Pediatr Oncol; 2000 Feb;34(2):125-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated moderate dose radiation, intrathecal chemotherapy, and repetitive reinduction/reconsolidation systemic therapy for central nervous system relapse of acute lymphoblastic leukemia in children.
  • BACKGROUND: We assessed efficacy and morbidity of chemotherapy and 1, 800 cGy of hypofractionated craniospinal irradiation (CSI) in children with central nervous system (CNS) relapse following first remisssion of acute lymphoblastic leukemia (ALL).
  • PROCEDURE: Nineteen patients with isolated CNS relapse and 4 with combined CNS/marrow or CNS/testicular relapse received treatment according to Children's Hospital of Philadelphia (CHOP) protocols CHP-449 and CHP-497.
  • CNS treatment included intrathecal methotrexate, cytarabine, and hydrocortisone and 1,800 cGy CSI in 16 fractions over 12 months.
  • Systemic therapy consisted of reinductions with vincristine, prednisone, and daunorubicin and reconsolidations with cytarabine, etoposide, and L-asparaginase every 56 days for 2 years.
  • Events include 2 second CNS, 4 marrow, 1 testicular, and 2 testicular/marrow relapses and 1 secondary leukemia.
  • Three patients have significant treatment-related reduction in stature.
  • CONCLUSIONS: Lower dose, hypofractionated CSI, intrathecal chemotherapy, and moderately intensive systemic chemotherapy provide excellent disease control for patients with late isolated CNS or combined marrow and CNS relapse.
  • Children with brief first remissions remain at substantial risk of subsequent relapse with this therapy, especially in the marrow and testes.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Neoplasm Recurrence, Local / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Radiotherapy Dosage. Survival Rate

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10657874.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


7. Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT: Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A; 2006 Nov 14;103(46):17426-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents.
  • Additivity, synergy, or competition was observed with MIS and rapamycin, AzadC, doxorubicin, cisplatin, and paclitaxel, suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Biomed Sci. 1994 Jun;51(2):147-57 [8049612.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):850-6 [9041185.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4525-30 [7553621.001]
  • [Cites] Am J Anat. 1977 Jul;149(3):353-75 [879051.001]
  • [Cites] J Surg Res. 1977 Aug;23(2):141-8 [886843.001]
  • [Cites] Science. 1979 Aug 31;205(4409):913-5 [472712.001]
  • [Cites] Am J Anat. 1979 Oct;156(2):265-84 [506954.001]
  • [Cites] Dev Biol. 1982 Jul;92(1):16-26 [7106377.001]
  • [Cites] Dev Biol. 1982 Jul;92(1):27-40 [7106385.001]
  • [Cites] Cancer Res. 1985 Oct;45(10):4970-9 [3861241.001]
  • [Cites] Cell. 1986 Jun 6;45(5):685-98 [3754790.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2101-6 [2009529.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):466-71 [1732773.001]
  • [Cites] Cancer Res. 1992 Mar 1;52(5):1182-6 [1531323.001]
  • [Cites] Protein Expr Purif. 1992 Jun;3(3):236-45 [1392620.001]
  • [Cites] Development. 1994 Jan;120(1):189-97 [8119126.001]
  • [Cites] Oncogene. 1995 Sep 21;11(6):1211-6 [7566983.001]
  • [Cites] Nat Med. 1995 Jul;1(7):686-92 [7585152.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):160-5 [8536608.001]
  • [Cites] Cell. 1996 Aug 9;86(3):435-44 [8756725.001]
  • [Cites] N Engl J Med. 1997 May 22;336(21):1480-6 [9154766.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2825-31 [9661897.001]
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):51-5 [10094880.001]
  • [Cites] Development. 1999 Jun;126(11):2551-61 [10226013.001]
  • [Cites] Endocrinology. 1999 Oct;140(10):4732-8 [10499532.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):111-6 [15618407.001]
  • [Cites] Nat Med. 2005 Jan;11(1):63-70 [15619626.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13831-8 [10570158.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3488-99 [10589763.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):27973-8 [10854429.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28371-9 [10874041.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):37101-9 [10958795.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3214-9 [11248058.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3393-7 [11248089.001]
  • [Cites] Mol Endocrinol. 2001 Jun;15(6):936-45 [11376112.001]
  • [Cites] Mol Endocrinol. 2001 Jun;15(6):946-59 [11376113.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):26799-806 [11356848.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):239-44 [11773638.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 5;766(1):89-98 [11820299.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2640-6 [12171896.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):408-10 [12368913.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1389-97 [12649204.001]
  • [Cites] Mol Cell Endocrinol. 2003 Dec 15;211(1-2):43-9 [14656475.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51703-12 [14532292.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15601-6 [14671316.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2737-46 [14576155.001]
  • [Cites] Front Biosci. 2004 Jan 1;9:619-31 [14766396.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):759-67 [14999786.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):1-8 [15385103.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6779-88 [15501954.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3948-56 [15883410.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7889-96 [16204015.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16421-5 [16260730.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1593-8 [16533786.001]
  • [Cites] Nature. 2006 Mar 30;440(7084):702-6 [16572177.001]
  • [Cites] Development. 2006 Jun;133(12):2359-69 [16687449.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Mol Endocrinol. 1994 Aug;8(8):1006-20 [7997230.001]
  • (PMID = 17088539.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K24 CA109416; United States / NCI NIH HHS / CA / U01 CA084242; United States / NCI NIH HHS / CA / R01 CA017393; United States / NCI NIH HHS / CA / CA 17393; United States / NCI NIH HHS / CA / 1K24 CA109416; United States / NCI NIH HHS / CA / P50 CA083638; United States / NICHD NIH HHS / HD / HD 32212
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Immunoglobulin G; 0 / Receptors, Peptide; 0 / Receptors, Transforming Growth Factor beta; 0 / Testicular Hormones; 0 / anti-Mullerian hormone receptor; 0 / antineoplastic agent K 18; 776B62CQ27 / decitabine; 80497-65-0 / Anti-Mullerian Hormone; M801H13NRU / Azacitidine; P88XT4IS4D / Paclitaxel; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ PMC1859945
  •  go-up   go-down


8. Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT: Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res; 2002 Aug;8(8):2640-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: To test the efficacy of highly purified MIS against ovarian cancer cell lines in vivo, we treated immunosuppressed mice with MIS after implanting OVCAR 8 or IGROV 1 human ovarian cancer cells beneath the renal capsules and measured tumor volume over time.
  • RESULTS: The average graft size ratio (change in size compared with starting size) of the OVCAR 8 tumor implants was larger in the control animals than in animals treated for 2 weeks (P < 0.019) or 3 weeks (P < 0.001) with parenteral MIS, or after treating with MIS produced from transfected cells, which impregnated the biodegradable mesh (P = 0.02).
  • CONCLUSIONS: Highly purified recombinant human MIS, delivered parenterally, or MIS produced endogenously causes inhibition of human ovarian cancer cell lines in vivo, providing convincing preclinical evidence to support the use of MIS as a parenteral agent for the treatment of ovarian cancer.
  • [MeSH-major] Glycoproteins. Growth Inhibitors / therapeutic use. Ovarian Neoplasms / drug therapy. Testicular Hormones / therapeutic use
  • [MeSH-minor] Animals. Anti-Mullerian Hormone. CHO Cells. Cricetinae. Female. Humans. Mice. Mice, Nude. Mice, SCID. Mullerian Ducts / immunology. Neoplasm Transplantation. Recombinant Proteins / therapeutic use. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12171896.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / 5R01HD-32112-08; United States / NCI NIH HHS / CA / CA71345-04; United States / NCI NIH HHS / CA / R01CA17393; United States / NCI NIH HHS / CA / T 32CA71345-06
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Growth Inhibitors; 0 / Recombinant Proteins; 0 / Testicular Hormones; 80497-65-0 / Anti-Mullerian Hormone
  •  go-up   go-down


9. Carver BS, Al-Ahmadie H, Sheinfeld J: Adult and pediatric testicular teratoma. Urol Clin North Am; 2007 May;34(2):245-51; abstract x
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult and pediatric testicular teratoma.
  • Although pure testicular teratomas in prepubertal boys have not been reported to metastasize, testicular teratomas in adults are associated with clinical metastases in 60% of cases.
  • Teratoma has a diverse biological potential, with propensity for local growth, distant metastases, and transformation to somatic malignant cell types.
  • Because of the chemoresitant nature of teratomas, complete surgical resection is the treatment of choice.
  • Since the biology of teratoma is unpredictable and it is frequently found in the retroperitoneum following chemotherapy for nonseminomatous germ-cell tumors, complete control of the retroperitoneum is advocated for all patients regardless of residual mass size.
  • [MeSH-major] Teratoma. Testicular Neoplasms
  • [MeSH-minor] Adult. Clinical Trials as Topic. Humans. Male. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484929.001).
  • [ISSN] 0094-0143
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


10. Agarwal PK, Palmer JS: Testicular and paratesticular neoplasms in prepubertal males. J Urol; 2006 Sep;176(3):875-81
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular and paratesticular neoplasms in prepubertal males.
  • PURPOSE: We reviewed the current diagnosis, staging and management of testicular and paratesticular neoplasms in prepubertal males.
  • MATERIALS AND METHODS: We performed a medical literature search in English using MEDLINE/PubMed that addressed testicular and/or paratesticular neoplasms in prepubertal males.
  • A palpable, nontender mass suggests the diagnosis and prompts scrotal ultrasound and tumor markers.
  • Although treatment for most primary tumors has historically been radical inguinal orchiectomy, most benign tumors can now be managed by testis sparing surgery.
  • The addition of radiation, chemotherapy and/or retroperitoneal lymph node dissection depends on tumor stage and histological type.
  • CONCLUSIONS: Although it is rare in children, any solid scrotal mass in prepubertal males warrants evaluation for possible testicular or paratesticular neoplasm.
  • [MeSH-major] Testicular Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890643.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


11. Yang WP, Zou Y, Huang CS, Zhang SZ, Xiao Q, Dai KL, Zhong HS, Xiong XJ: [Clinicopathologic and prognostic study of pediatric immature teratoma]. Zhonghua Bing Li Xue Za Zhi; 2007 Oct;36(10):666-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic and prognostic study of pediatric immature teratoma].
  • OBJECTIVE: To study the clinicopathologic features and biologic behavior of pediatric immature teratoma.
  • METHODS: The clinical data, pathologic features, immunohistochemical findings (for cyclin D1, P27 and Ki-67) and follow-up information of 39 cases of pediatric immature teratoma were analyzed.
  • RESULTS: Amongst the 39 cases studied, 12 arose in the sacrococcygeal region, 12 in testis, 5 in retroperitoneum, 4 in ovary, 4 in abdomen and 2 in mediastinum.
  • Seven of the cases contained foci of yolk sac tumor.
  • Immature neuroepithelial features used in histologic grading included the presence of primitive neural tubules, immature rosettes, undifferentiated neuroblastoma cells and primitive neuroectodermal structures.
  • Three of them, including 2 cases with histologic grade 3 (with or without yolk sac tumor component), recurred after operation.
  • On the other hand, p27 overexpression shows little correlation with tumor grade.
  • Sacrococcygeal immature teratoma occurring in patients younger than 1 year old and with low histologic grade do not require postoperative chemotherapy if the tumor is completely excised.
  • Similarly, for testicular immature teratoma occurring in patients below 1 year of age, regardless of tumor grading, need no adjunctive therapy.
  • On the other hand, ovarian immature teratoma with high histologic grade requires postoperative chemotherapy, regardless of age of the patients.
  • The presence of microscopic foci of yolk sac tumor is a useful predictor of recurrence in pediatric immature teratoma.
  • [MeSH-major] Ovarian Neoplasms / pathology. Retroperitoneal Neoplasms / pathology. Teratoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Cyclin D1 / metabolism. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / metabolism. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / surgery. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Ki-67 Antigen / metabolism. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / metabolism. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / surgery. Neoplasm Recurrence, Local. Neoplasm Staging. Proliferating Cell Nuclear Antigen / metabolism. Sacrococcygeal Region. Survival Rate. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18194599.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / alpha-Fetoproteins; 0 / p27 antigen; 136601-57-5 / Cyclin D1
  •  go-up   go-down


12. Cao Avellaneda E, Alarcón Martínez H, Fuster Soler JL, López Cubillana P, Llinares Riestra E, Pérez Albacete M: [Testicular and paratesticular prepuberal tumors: our experience and update on the topic]. Actas Urol Esp; 2005 Apr;29(4):355-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular and paratesticular prepuberal tumors: our experience and update on the topic].
  • OBJECTIVES: To evaluate the importance of testicular and paratesticular prepubertal tumors in our center and to make an update on the topic.
  • METHODS AND PATIENTS: Data from all patients diagnosed of testicular and paratesticular prepubertal tumors and treated in our pediatric oncology unit from January 1st 1998 to December 31st 2003 have been revised.
  • RESULTS: Seven cases are reported among one hundred and ninety patients (represents 3,68 percent of all treated tumors): five tumors affecting the testis and two cases of paratesticular tumors.
  • Pathology classification was as follows: one yolk sack tumor, one mature teratoma, two nongerminomatous testicular tumors (one Sertoli cell tumor and one unclassifiable), one Burkitt's lymphoma and two paratesticular rhabdomyosarcomas.
  • Primary approach was inguinal radical orchiectomy in all cases except neoadjuvant chemotherapy in the case of lymphoma and partial escrotectomy in one patient previously managed with transcrotal orchiectomy.
  • Rhabdomyosarcoma cases received adjuvant chemotherapy.
  • CONCLUSIONS: Testicular and paratesticular prepubertal tumors are rare.
  • Except for one patient affected of lymphoma, surgical primary approach have been essential for treatment.
  • [MeSH-major] Testicular Neoplasms / pathology
  • [MeSH-minor] Child. Humans. Infant. Male. Neoplasm Staging. Orchiectomy. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981422.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


13. Castellino SM, McLean TW: Pediatric genitourinary tumors. Curr Opin Oncol; 2007 May;19(3):248-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric genitourinary tumors.
  • PURPOSE OF REVIEW: We will review the 2005 and 2006 literature on pediatric genitourinary tumors.
  • RECENT FINDINGS: Survival continues to improve for primary renal, bladder/prostate and testicular tumors in childhood.
  • The addition of more intensive chemotherapy for anaplastic histology disease, recognition of loss of heterozygosity for chromosomes 1p and 16q as an adverse prognostic factor in favorable histology Wilms' tumor, and the utilization of molecular markers to better characterize all renal tumors will better enable individualized therapy.
  • Recognition and treatment of anaplastic histology and bilateral Wilms' tumor remains a challenge.
  • SUMMARY: Advances in molecular oncology, diagnostic imaging, surgical approaches and long-term follow-up of childhood cancer survivors drive risk-stratified therapy in pediatric genitourinary tumors.
  • [MeSH-major] Urogenital Neoplasms / diagnosis. Urogenital Neoplasms / therapy
  • [MeSH-minor] Child. Female. Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy. Loss of Heterozygosity. Male. Neoplasm Staging. Prognosis. Rhabdomyosarcoma / genetics. Rhabdomyosarcoma / metabolism. Wilms Tumor / diagnosis. Wilms Tumor / genetics. Wilms Tumor / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414644.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 66
  •  go-up   go-down


14. Köksal Y, Yalçin B, Uner A, Akyüz C, Han U, Büyükpamukçu M: Primary testicular Burkitt lymphoma in a child. Pediatr Hematol Oncol; 2005 Dec;22(8):705-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular Burkitt lymphoma in a child.
  • The left testis was found to be small with heterogeneous parenchyma by scrotal ultrasound (US) and other systemic investigations were negative for lymphoma involvement.
  • Ultrasound-guided fine-needle aspiration biopsy showed no evidence of involvement in the left testis.
  • Considering stage I Burkitt lymphoma, chemotherapy was started.
  • Following the first course, US findings changed: the volume of the left testis decreased and the parenchyma became homogeneous.
  • The left testis was considered to be involved by lymphoma at initial diagnosis and chemotherapy was intensified.
  • At the end of 5 months of chemotherapy the left testis was again heterogeneous in US.
  • The patient is under regular follow-up and is in complete remission 19 months after the end of chemotherapy.
  • Primary testicular lymphoma is quite rare in children and experience is limited.
  • Changes in testicular size and parenchyma by US should not necessarily indicate involvement by lymphoma in pubertal boys.
  • [MeSH-major] Burkitt Lymphoma. Scrotum / ultrasonography. Testicular Neoplasms
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Follow-Up Studies. Humans. Male. Neoplasm Staging. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16251177.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Göbel U, Calaminus G, Schneider DT, Koch S, Teske C, Harms D: The malignant potential of teratomas in infancy and childhood: the MAKEI experiences in non-testicular teratoma and implications for a new protocol. Klin Padiatr; 2006 Nov-Dec;218(6):309-14
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The malignant potential of teratomas in infancy and childhood: the MAKEI experiences in non-testicular teratoma and implications for a new protocol.
  • Since 1982, mature and immature teratomas have been recruited into the MAHO and MAKEI protocols of the German Society for Pediatric Oncology and Hematology (GPOH) for testicular and non-testicular germ cell tumors in order to study the epidemiology and clinical behaviour of teratomas.
  • Patients were registered in the epidemiologic German Childrens Cancer Registry and the GPOH Childrens Tumor Registry for pathological review.
  • Patients with immaturity grade 2 and 3 according to Gonzales-Crussi were eligible for adjuvant chemotherapy.
  • 1) EFS after complete tumor resection has been estimated to 0.96 +/- 0.01 in both observation periods.
  • 2) Incomplete tumor resection remains the main risk factor for relapse (EFS 0.55 +/- 0.09).
  • 4) In MAKEI 83/86/89 four newborns with teratoma died due to perioperative complications and nine children as a result of tumor progression, whereas in MAKEI 96 no newborn died, only one child died from tumor progression, and another child died during long time observation for another reason (meningitis).
  • 5) In accordance to the experience of the MAKEI 83/86/89 studies, no child of the MAKEI 96 study presented with yolk sac tumor at recurrence if adjuvant chemotherapy was administered during first-line treatment because of immaturity.
  • In contrast, more than half of the children with tumor recurrence after watch and wait strategy had yolk sac tumor in addition to teratoma.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Chi-Square Distribution. Child. Child, Preschool. Data Interpretation, Statistical. Disease Progression. Female. Humans. Infant. Infant, Newborn. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Neoplasms, Germ Cell and Embryonal / pathology. Ovary / pathology. Prospective Studies. Randomized Controlled Trials as Topic. Sacrococcygeal Region. Sex Factors. Treatment Outcome. World Health Organization

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17080332.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


16. Heidenreich A: Clinical stage I nonseminomatous testicular germ-cell tumors: surgery or watchful waiting, still an issue? Curr Opin Urol; 2002 Sep;12(5):427-30
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical stage I nonseminomatous testicular germ-cell tumors: surgery or watchful waiting, still an issue?
  • PURPOSE OF REVIEW: The optimal management for clinical stage I nonseminomatous testicular germ-cell tumors is still a subject open to controversy.
  • It is the purpose, here, to present a critical review of recent developments concerning primary therapy for clinical stage I nonseminomatous testicular germ-cell tumors and to identify potential new prognostic risk factors predicting occult metastatic retroperitoneal lymph node disease.
  • RECENT FINDINGS: In accordance with the primary goal to improve quality of life, to protect fertility and to reduce long-term toxicity in survivors of testicular cancer, the major advantage of surveillance protocols is that adjuvant therapy will be administered only to those patients who require therapy.
  • Primary nerve-sparing retroperitoneal lymph-node dissection has diagnostic and therapeutic capabilities in low-volume disease; as local relapses are extremely rare, an effective and cost-saving follow-up concentrating on pulmonary recurrences can be initiated.
  • Nerve-sparing retroperitoneal lymph node dissection represents the initial approach for mature teratomas; patients with purely embryonal carcinoma have a high risk for systemic relapses and might be better served by primary chemotherapy.
  • The advantages and disadvantages of both treatment modalities must be discussed extensively with the patient, and it will be basically his decision as to which therapeutic approach is chosen.
  • [MeSH-major] Germinoma / pathology. Germinoma / therapy. Testicular Neoplasms / pathology. Testicular Neoplasms / therapy
  • [MeSH-minor] Humans. Lymphatic Metastasis. Male. Neoplasm Staging. Prognosis. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12172431.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


17. Calaminus G, Schneider DT, Weissbach L, Schönberger S, Okpanyi V, Leuschner I, Poremba C, Göbel U: Survival after an antiangiogenetic therapy and surgery in a wide spread growing teratoma originating from a testicular mixed malignant germ cell tumor. Klin Padiatr; 2009 May-Jun;221(3):136-40
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after an antiangiogenetic therapy and surgery in a wide spread growing teratoma originating from a testicular mixed malignant germ cell tumor.
  • Growing teratoma is still an often unsolved problem especially in male with mixed malignant GCTs of the testis or the mediastinum.
  • This specific situation with progressive tumor growth and simultaneous normalization of tumor markers during or after treatment of malignant GCTs with teratomatous elements is judged as a fatal situation if this situation can not be controlled by extensive surgery, as teratoma are not sensible to chemotherapy or irradiation.
  • Here, we report the case history of a 17-year old male patient with a testicular malignant GCT and wide spread lymph node metastases, who developed a rapidly progressive growing teratoma within the lymph node metastases.
  • Within the molecular profile of the tumor we could find a cytogenetic picture typically found in malignant adult GCTs.
  • In view of the bulky abdominal, thoracic and cervical metastases and the uncontrolled tumor progression, the situation was considered incurable.
  • However, following an individual treatment attempt, this patient was treated with a four-agent combination of drugs with antiangiogenetic potential as well as low-dose cyclic chemotherapy.
  • We therefore would like to highlight this treatment approach in unresectable growing teratoma and would like to stimulate further research and collaboration to come to an optimized treatment suggestion for this group of poor prognostic patients.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / surgery. Lymph Node Excision. Lymphatic Metastasis. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / surgery. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / surgery. Teratoma / drug therapy. Teratoma / surgery. Testicular Neoplasms / drug therapy. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Bevacizumab. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Follow-Up Studies. Humans. Interferon-alpha / administration & dosage. Interferon-alpha / adverse effects. Lymph Nodes / blood supply. Lymph Nodes / pathology. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Recombinant Proteins. Reoperation. Salvage Therapy. Survival Rate. Thalidomide / administration & dosage. Thalidomide / adverse effects. Tomography, X-Ray Computed. Vinblastine / administration & dosage. Vinblastine / adverse effects

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Klin Padiatr. 2009 May-Jun;221(3):134-5 [19437359.001]
  • (PMID = 19437360.001).
  • [ISSN] 1439-3824
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Interferon-alpha; 0 / Recombinant Proteins; 2S9ZZM9Q9V / Bevacizumab; 4Z8R6ORS6L / Thalidomide; 5V9KLZ54CY / Vinblastine; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


18. Grier DD, Eskew A, White T, McLean TW: An unusual case of acute myeloid leukemia: late isolated testicular relapse followed by isolated central nervous system relapse. Pediatr Blood Cancer; 2010 Dec 1;55(6):1231-3
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of acute myeloid leukemia: late isolated testicular relapse followed by isolated central nervous system relapse.
  • Testicular relapse of acute myeloid leukemia without bone marrow involvement is a rare event.
  • We describe a case of an 18-year-old male who had an isolated testicular relapse 86 months (7.2 years) from original diagnosis.
  • He was treated with surgery only, without adjuvant therapy.
  • The patient then developed central nervous system involvement 9 months later.
  • He was treated with intrathecal chemotherapy and systemic reinduction, followed by a stem cell transplant.
  • This patient had a 7.2-year period between original diagnosis and the testicular relapse of acute myeloid leukemia.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Leukemia, Myeloid, Acute / surgery. Neoplasm Recurrence, Local / diagnosis. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Injections, Spinal. Male. Thioguanine / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20589624.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; FTK8U1GZNX / Thioguanine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


19. Stewart RJ, Martelli H, Oberlin O, Rey A, Bouvet N, Spicer RD, Godzinski J, Stevens MC, International Society of Pediatric Oncology: Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology. J Clin Oncol; 2003 Mar 1;21(5):793-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology.
  • PURPOSE: To report the results of the Malignant Mesenchymal Tumors studies (MMT 84 and 89) of the International Society of Pediatric Oncology (SIOP) in males with nonmetastatic paratesticular rhabdomyosarcoma.
  • Disease was staged according to the SIOP tumor-node-metastasis staging system.
  • Treatment was stratified by stage.
  • In the MMT 89 study, males with completely resected tumors at diagnosis received less chemotherapy (vincristine and dactinomycin) than patients in the MMT 84 study (ifosfamide, vincristine, and dactinomycin).
  • Thirty-one tumors were larger than 5 cm, and 13 males were older than 10 years with a tumor larger than 5 cm.
  • CONCLUSION: Males with paratesticular RMS have an excellent prognosis except for a selected group of patients older than 10 years or with tumor greater than 5 cm.
  • Intensified chemotherapy incorporating alkylating agents for this subgroup may be preferred to the use of systematic lymphadenectomy to improve survival while minimizing the burden of therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dactinomycin / therapeutic use. Ifosfamide / therapeutic use. Mesenchymoma / drug therapy. Rhabdomyosarcoma / drug therapy. Testicular Neoplasms / drug therapy. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Humans. Infant. Lymph Node Excision. Male. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Salvage Therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12610176.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; UM20QQM95Y / Ifosfamide; IVA protocol; SIOP protocol
  •  go-up   go-down


20. Wiener ES, Anderson JR, Ojimba JI, Lobe TE, Paidas C, Andrassy RJ, Raney RB, Qualman SJ, Donaldson SS, Maurer HM, Link MP, Crist WM, Grier HE: Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? Semin Pediatr Surg; 2001 Aug;10(3):146-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Intergroup Rhabdomyosarcoma Study Group (IRSG) required ipsilateral RPLND (IRPLND) for all patients with PTRMS treated on IRS-III (1984-91), but changed to clinical evaluation of RPLNs using computerized tomography (CT) in IRS-IV (1991 through 1997).
  • Nodal radiation therapy was administered only to patients with RPLNs recognized as positive; such patients received more intensive chemotherapy as well.
  • Furthermore, adolescents with recognized group II tumors experienced better 3-year FFS than those with group I tumors on IRS-IV (100% versus 68%, P =.06), most likely as a result of receiving radiotherapy and intensified chemotherapy.
  • Furthermore, adolescent boys with group I tumors experienced worse FFS than those with Group II tumors on IRS-IV, probably because some patients with group II tumors were not identified by CT imaging and thus received less effective therapy.
  • These data suggest that adolescents should have ipsilateral RPLN dissection as part of their routine staging, and those with positive lymph nodes require intensified chemotherapy as well as nodal irradiation.
  • [MeSH-major] Lymph Node Excision. Neoplasm Staging. Retroperitoneal Space / surgery. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / surgery
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Humans. Male. Survival Rate / trends. Testicular Neoplasms. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company
  • (PMID = 11481652.001).
  • [ISSN] 1055-8586
  • [Journal-full-title] Seminars in pediatric surgery
  • [ISO-abbreviation] Semin. Pediatr. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA24507; United States / NCI NIH HHS / CA / CA72989
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


21. Suita S, Shono K, Tajiri T, Takamatsu T, Mizote H, Nagasaki A, Inomata Y, Hara T, Okamura J, Miyazaki S, Kawakami K, Eguchi H, Tsuneyoshi M, Committee for Pediatric Solid Malignant Tumors in the Kyushu Area: Malignant germ cell tumors: clinical characteristics, treatment, and outcome. A report from the study group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan. J Pediatr Surg; 2002 Dec;37(12):1703-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant germ cell tumors: clinical characteristics, treatment, and outcome. A report from the study group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan.
  • PURPOSE: This study aims to assess the prognostic factors and optimal treatments for malignant germ cell tumors (MGCT) in childhood.
  • The prognostic factors and treatments were assessed based on the 5-year survival rate. RESULTS:.
  • (1) Stage: 100% for stage I (n = 54), 75.0% for stage II (n = 4), 67.3% for stage III (n = 14), and 54.8% for stage IV (n = 33); Unknown: n = 12. (2) Primary site: 93.4% for the testis (n = 52), 86.7% for the ovary (n = 31), 56.9% for the sacrococcygeal (n = 21), and 60.6% for others (n = 12); unknown: n = 1. (3) Surgical intervention for primary tumor: 100% for stage I with a complete resection (n = 53), 78.4% for stage III, IV with a complete resection (n = 26), and 33.3% for stage III, IV with an incomplete resection (n = 21). (4) Type of chemotherapy for the stage III and IV: 83.9% for the PVB (cisplatin, vinblastin, bleomycin; n = 13), 66.7% for the VAC (vincristine, actinomycin D, cyclophosphamide; n = 6), and 47.1% for other regimens (n = 25).
  • Radical complete resection alone is a sufficient treatment for localized MGCT.
  • The PVB regimen is optimal chemotherapy for advanced MGCT; however, high-risk cases still may require more aggressive treatment.
  • [MeSH-major] Germinoma / diagnosis. Germinoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Neoplasm Staging. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / surgery. Prognosis. Retrospective Studies. Survival Rate. Testicular Neoplasms / diagnosis. Testicular Neoplasms / epidemiology. Testicular Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • [CommentIn] J Urol. 2003 Sep;170(3):1040 [12926414.001]
  • (PMID = 12483635.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Schneider DT, Calaminus G, Wessalowski R, Pathmanathan R, Harms D, Göbel U: Therapy of advanced ovarian juvenile granulosa cell tumors. Klin Padiatr; 2002 Jul-Aug;214(4):173-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy of advanced ovarian juvenile granulosa cell tumors.
  • Among these, juvenile granulosa cell tumors (JGCT) constitute the largest subgroup of ovarian sex cord-stromal tumors during childhood and adolescence.
  • In local disease (FIGO stage I), the beneficial role of tumor-ovarectomy is well established.
  • In contrast, life expectancy in patients with advanced JGCT (FIGO stage >/= II) is short even after complete tumor resection.
  • The current literature provides only limited and inconclusive data regarding the value of adjuvant chemotherapy in such patients with advanced disease.
  • PATIENTS AND METHODS: Therefore, we analyzed the patients with FIGO stage >/= II JGCT who were prospectively documented as follow-up patients of the German MAKEI trials for non-testicular germ cell tumors and received the recommended cisplatin-based chemotherapy in an adjuvant setting.
  • Two patients received laparoscopic tumor resection, which was incomplete in both.
  • All patients received 4 or 6 cycles of adjuvant cisplatin-based three-agent chemotherapy in analogy to the current therapeutic concept applied in malignant germ cell tumors.
  • One patient with a large tumor and multiple peritoneal metastases additionally received 40 Gy abdominal irradiation.
  • RESULTS: All patients achieved complete clinical remission after initial surgery and adjuvant chemotherapy.
  • One patient developed a metachronous tumor of the contralateral ovary after 126 months follow-up and is still alive but currently in therapy of another recurrence.
  • Another patient suffered a tumor recurrence after 12 months but achieved a second complete remission with cisplatin chemotherapy after a follow-up of currently 4 months.
  • One patient achieved complete clinical remission but suffered a diffuse peritoneal tumor recurrence with massive ascites and finally died as a result of tumor progression.
  • In summary, at the time of this report 6 of 7 patients are alive after a median of 47 (15 - 138) months.
  • CONCLUSION: This analysis clearly demonstrates that advanced JGCT can be successfully treated with surgery followed by adjuvant cisplatin-based chemotherapy.
  • Therefore, this study reveals encouraging therapeutic perspectives in these otherwise fatal tumors that merit further investigation in a prospective cooperative trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulosa Cell Tumor / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Female. Follow-Up Studies. Germany. Humans. Neoplasm Staging. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12165898.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Bisogno G, Roganovich J, Sotti G, Ninfo V, di Montezemolo LC, Donfrancesco A, Mascarin M, Carli M: Desmoplastic small round cell tumour in children and adolescents. Med Pediatr Oncol; 2000 May;34(5):338-42
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Desmoplastic small round cell tumour (DSRCT) is a rare highly aggressive neoplasm, and clinical studies are scarce.
  • PROCEDURE: We report six cases of children and adolescents (median age 14 years, range 6.9-17.5) with DSRCT (5 abdominal, 1 paratesticular) registered by the Italian Cooperative Group (ICG) for soft tissue sarcoma over a 9-year period.
  • Patients received a multidisciplinary treatment, including aggressive initial or delayed surgery and radiotherapy.
  • Chemotherapy regimen was based on the use of ifosfamide, vincristine, dactinomycin, and a few doses of antharacyclines (doxorubicin or epirubicin).
  • All patients received multidrug chemotherapy, and tumour reduction was obtained in the 4 evaluable patients.
  • CONCLUSIONS: DSRCT is a chemosensitive tumour, but survival rates remain disappointing despite aggressive multimodality therapy.
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / radiotherapy. Abdominal Neoplasms / surgery. Adolescent. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Dactinomycin / administration & dosage. Disease-Free Survival. Humans. Ifosfamide / administration & dosage. Male. Neoplasm Recurrence, Local. Prognosis. Remission Induction. Salvage Therapy. Survival Rate. Testicular Neoplasms / drug therapy. Testicular Neoplasms / radiotherapy. Testicular Neoplasms / surgery. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10797355.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


24. Kulkarni KP, Marwaha RK, Trehan A, Bansal D: Pattern of relapsed disease in childhood all: experience from a single tertiary care center in North India. Pediatr Hematol Oncol; 2009 Sep;26(6):398-406
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of relapsed disease in childhood all: experience from a single tertiary care center in North India.
  • The majority relapsed while on chemotherapy.
  • Isolated testicular relapse was seen in 17 (15.3%) of the 111 boys who suffered a relapse.
  • Relapse of disease while on chemotherapy and high incidence of CNS and testicular relapse indicate the need for reappraisal of treatment protocols.
  • [MeSH-major] Bone Marrow Neoplasms / pathology. Central Nervous System Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Cranial Irradiation. Female. Humans. India. Infant. Male. Prognosis. Remission Induction. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19657989.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Celkan TT, Bariş S, Ozdemir N, Ozkan A, Apak H, Doğru O, Karaman S, Canbolat A, Ozdil M, Aki H, Adaletli I, Kurugoglu S, Hallac M, Yildiz I: Treatment of pediatric Burkitt lymphoma in Turkey. J Pediatr Hematol Oncol; 2010 Oct;32(7):e279-84
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of pediatric Burkitt lymphoma in Turkey.
  • This study aimed to assess the demographic data and treatment results of children who were diagnosed with Burkitt lymphoma and treated according to the Berlin-Frankfurt-Münster-95 (BFM) protocol in a single institution.
  • Primary tumor sites were abdomen (70.8%), head and neck (22.9%), peripheral lymph node (2%), bone (2%), and testis (2%).
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Asparaginase / administration & dosage. Asparaginase / adverse effects. Biopsy. Bone Neoplasms / drug therapy. Bone Neoplasms / mortality. Bone Neoplasms / pathology. Child. Child, Preschool. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Disease-Free Survival. Female. Follow-Up Studies. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / pathology. Humans. Lymphatic Metastasis. Male. Multivariate Analysis. Neoplasm Staging. Predictive Value of Tests. Prednisone / administration & dosage. Prednisone / adverse effects. Risk Factors. Survival Analysis. Testicular Neoplasms / drug therapy. Testicular Neoplasms / mortality. Testicular Neoplasms / pathology. Turkey / epidemiology. Vincristine / administration & dosage. Vincristine / adverse effects

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736844.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


26. Bernal F, Raman JD: Exploration of treatment options for the management of stage I testicular seminoma. Expert Rev Anticancer Ther; 2008 Jul;8(7):1081-90
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploration of treatment options for the management of stage I testicular seminoma.
  • Men with clinical stage I seminomas have an excellent chance of achieving a cure irrespective of the treatment option selected.
  • With such high disease-specific survival rates, attention has turned to reducing treatment-related morbidity.
  • Adjuvant radiotherapy to the para-aortic retroperitoneal lymph nodes in conjunction with orchidectomy has been the standard treatment since the mid-1990s.
  • There is some evidence, however, suggesting potential deleterious long-term sequelae from radiation treatment.
  • Adjuvant chemotherapy has gained support as an acceptable adjuvant treatment strategy for stage I seminoma.
  • While long-term studies are limited, short-term data regarding the therapeutic efficacy of single-agent carboplatin are promising.
  • Finally, surveillance following orchidectomy is an attractive option for motivated patients interested in avoiding immediate adjuvant therapy.
  • It may be the optimal choice for compliant men who are able to handle the mental burden of not receiving active treatment.
  • [MeSH-major] Seminoma / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Male. Neoplasm Staging. Orchiectomy. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18588453.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  • [Number-of-references] 59
  •  go-up   go-down


27. Schlatter M, Rescorla F, Giller R, Cushing B, Vinocur C, Colombani P, Cullen J, London W, Davis M, Lauer S, Olson T, Children's Cancer Group, Pediatric Oncology Group: Excellent outcome in patients with stage I germ cell tumors of the testes: a study of the Children's Cancer Group/Pediatric Oncology Group. J Pediatr Surg; 2003 Mar;38(3):319-24; discussion 319-24
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent outcome in patients with stage I germ cell tumors of the testes: a study of the Children's Cancer Group/Pediatric Oncology Group.
  • BACKGROUND/PURPOSE: The aim of this study was to correlate outcomes in patients with stage I testicular germ cell tumors with compliance to surgical guidelines and to confirm previous single-institution experiences that show excellent disease-free survival rates when treated with orchiectomy alone.
  • METHODS: Sixty-three patients were entered into this intergroup study (Children's Cancer Group 8881/Pediatric Oncology Group 9048) between 1990 and 1996.
  • Failure of tumor marker normalization or subsequent elevation suggested advanced disease requiring further surgery and chemotherapy.
  • All patients with relapse or progression of their disease appear to be cured with further surgical excision and chemotherapy.
  • [MeSH-major] Germinoma / surgery. Orchiectomy. Testicular Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Child, Preschool. Disease-Free Survival. Humans. Infant. Infant, Newborn. Male. Neoplasm Staging. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003, Elsevier Science (USA). All rights reserved.
  • (PMID = 12632342.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


28. Wu HY, Snyder HM 3rd: Pediatric urologic oncology: bladder, prostate, testis. Urol Clin North Am; 2004 Aug;31(3):619-27, xi
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric urologic oncology: bladder, prostate, testis.
  • Although treatment for bladder, prostate, and testis cancer comprises a large part of adult urologic practice, the tumors that affect these organs in children are rare.
  • Rhabdomyosarcoma,which affects the bladder, prostate, vaginal, and paratesticular areas,is treated with a combination of surgery, chemotherapy, and radiation.
  • Most transitional cell carcinomas of the bladder and prepubertal testis tumors are managed surgically owing to the low stage at presentation.
  • Application of the technical advances learned in adults with tumors of the bladder, prostate, and testis, combined with an understanding of the difference in tumor biology, helps urologists improve the treatment of these tumors in children.
  • [MeSH-major] Prostatic Neoplasms / therapy. Rhabdomyosarcoma. Testicular Neoplasms / therapy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Child. Combined Modality Therapy. Cystectomy. Endodermal Sinus Tumor / surgery. Female. Humans. Leydig Cell Tumor / surgery. Male. Neoplasm Staging. Orchiectomy. Risk Assessment. Uterine Neoplasms / therapy. Vaginal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15313070.001).
  • [ISSN] 0094-0143
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


29. Perentesis JP, Bhatia S, Boyle E, Shao Y, Shu XO, Steinbuch M, Sather HN, Gaynon P, Kiffmeyer W, Envall-Fox J, Robison LL: RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia; 2004 Apr;18(4):685-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.
  • We sought to define the frequency and spectrum, and possible prognostic importance, of N- and K-RAS mutations in children with ALL treated with contemporary therapy.
  • Leukemic blast DNA from 870 children was analyzed for the presence of activating mutations in the N- or K-RAS oncogenes using a sensitive mutation detection algorithm.
  • RAS mutations were present in the blasts of 131 (15.1%) pediatric ALL patients.
  • The presence of N- or K-RAS mutations was not associated with white blood cell count at diagnosis, sex, race, extramedullary testicular involvement, central nervous system disease, or NCI/CTEP ALL Risk Group.
  • While N- and K-RAS mutations can be identified in 15% of children with newly diagnosed ALL, they do not represent a significant risk factor for outcome using contemporary chemotherapy regimens.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. DNA Mutational Analysis. DNA, Neoplasm / genetics. Female. Humans. Infant. Infant, Newborn. Male. Molecular Epidemiology. Prognosis. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14990973.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES07819
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


30. Arya LS, Kotikanyadanam SP, Bhargava M, Saxena R, Sazawal S, Bakhshi S, Khattar A, Kulkarni KP, Adde M, Vats TS, Magrath I: Pattern of relapse in childhood ALL: challenges and lessons from a uniform treatment protocol. J Pediatr Hematol Oncol; 2010 Jul;32(5):370-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of relapse in childhood ALL: challenges and lessons from a uniform treatment protocol.
  • There were 23 (57.5%) isolated bone marrow (BM), 7 (17.5%) isolated central nervous system (CNS), 2 (5%) isolated testicular, 5 (12.5%) BM+testes and 1 each of BM+CNS, CNS+testes, and isolated bone relapses.
  • Twenty-seven children (67.5%) relapsed on-therapy whereas 13 (32.5%) relapsed posttherapy.
  • All 9 CNS relapses occurred on-therapy whereas 5/8 (62.5%) of testicular relapses occurred posttherapy.
  • High-risk features such as age less than 1 year and greater than 10 years (P=0.047) and white cell count greater than 50.0 x 10(9)/L (P=0.044) were significantly more frequent in patients with early on-therapy relapse than in patients with off-therapy relapse.
  • Modest survival outcome, relapse while on chemotherapy and the higher incidence of CNS and testicular relapse indicate the need for reappraisal of our treatment protocol.
  • There is a need of identifying risk factors and high-risk groups in our set of patients and risk-stratified intensification of chemotherapy in them.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Neoplasms / therapy. Brain Neoplasms / mortality. Neoplasm Recurrence, Local / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. Female. Humans. Infant. Male. Radiotherapy Dosage. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20463606.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Akramipour R, Zargooshi J, Rahimi Z: Infant with concomitant presence of hernia/hydrocele and primary paratesticular neuroblastoma: a diagnostic and therapeutic challenge. J Pediatr Hematol Oncol; 2009 May;31(5):349
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infant with concomitant presence of hernia/hydrocele and primary paratesticular neuroblastoma: a diagnostic and therapeutic challenge.
  • We report an 8-month-old boy with stage 1 neuroblastoma, whose "testicular tumor" was removed during a "radical orchiectomy" by a pediatric surgeon who encountered a scrotal mass during a hernia repair.
  • Pathologic examination of the specimen suggested seminoma and the surgeon sent the patient for cisplatin-based chemotherapy.
  • However, follow-up examination showed a normal testis.
  • The patient is tumor free after 36 months of follow-up.
  • This case shows that in presence of hernia, distorted anatomy, and inguinal testis, paratesticular tumors can be misdiagnosed for the testis and cause great diagnostic and therapeutic difficulty.
  • [MeSH-major] Genital Neoplasms, Male / complications. Genital Neoplasms, Male / pathology. Hernia, Inguinal / complications. Neuroblastoma / complications. Neuroblastoma / pathology. Testicular Hydrocele / complications
  • [MeSH-minor] Diagnostic Errors. Female. Humans. Male. Neoplasm Staging. Orchiectomy. Scrotum / pathology. Scrotum / surgery. Testis / blood supply. Testis / cytology. Testis / surgery

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415016.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Terenziani M, Piva L, Spreafico F, Salvioni R, Massimino M, Luksch R, Cefalo G, Casanova M, Ferrari A, Polastri D, Mazza E, Bellani FF, Nicolai N: Clinical stage I nonseminomatous germ cell tumors of the testis in childhood and adolescence: an analysis of 31 cases. J Pediatr Hematol Oncol; 2002 Aug-Sep;24(6):454-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical stage I nonseminomatous germ cell tumors of the testis in childhood and adolescence: an analysis of 31 cases.
  • A 20-year single-institution experience of clinical stage I nonseminomatous germ cell tumors of the testis (NSGCTT) in childhood and adolescents was reviewed in relation to clinical characteristics, treatment modalities, and survival.
  • After orchiectomy, the children were assigned to surveillance and the adolescents to active treatment: 16 underwent retroperitoneal lymph node dissection (RPLND) and 1 had adjuvant cisplatin-based chemotherapy because of a high-risk histology.
  • All three children were treated with cisplatin-based chemotherapy with or without surgery.
  • All were treated with cisplatin-based chemotherapy with or without surgery.
  • In particular, almost all the childhood cases had the same yolk sac tumor histology, the children tended to have localized disease, and an increased alpha-fetoprotein level had a very high predictive value, suggesting that follow-up should include AFP measurements.
  • A conservative approach is the best option in children, while adolescent NSGCTT behaves like the adult disease and management must include similar treatment strategies.
  • [MeSH-major] Endodermal Sinus Tumor / pathology. Germinoma / pathology. Teratoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Cisplatin / therapeutic use. Combined Modality Therapy. Follow-Up Studies. Humans. Infant. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Staging. Orchiectomy. Retrospective Studies. Risk Factors. Survival Rate. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12218592.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Cecchetto G, Guglielmi M, Inserra A, Zanetti I, Dall'Igna P, Gigante C, Carli M, Italian Cooperative Group on Soft-tissue Sarcomas: Primary re-excision: the Italian experience in patients with localized soft-tissue sarcomas. Pediatr Surg Int; 2001 Sep;17(7):532-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary re-excision: the Italian experience in patients with localized soft-tissue sarcomas.
  • Primary re-excision (PRE) is a wide, non-mutilating procedure carried out in patients with soft-tissue sarcomas (STS) when microscopic residuals are left after initial excision or when there are insufficient data on its completeness.
  • The primary sites were the extremities in 20, paratesticular 15, trunk 9, head-neck-non-parameningeal (HNnPM) 6, bladder 1, other sites in 2; the tumor (T) status was T1a in 30, T1b in 10, T2a in 9, and T2b in 4; the median interval between primary surgery and PRE was 36 days.
  • Of the 53 patients, 45 had complete histologic excision of the tumor (residuals were found in 21/45 specimens) and subsequently received chemotherapy (CT) alone: 39/45 are in their first complete remission (CR) with a median follow-up of 53 months; 6/45 (3 RMS, 3 NRSTS) relapsed, 4 locally (2 extremities, 2 trunk), and 1 of these died of progressive disease, and 2 with metastatic spread died of their disease.
  • The histologic types and the presence of residuals at PRE did not predict the failures; PRE was effective especially in extremity, trunk, and paratesticular sites, whereas its role was uncertain in large sarcomas over 5 cm in size.
  • [MeSH-major] Rhabdomyosarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Head and Neck Neoplasms / surgery. Humans. Infant. Italy. Male. Neoplasm Staging. Testicular Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11666052.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


34. Lo Curto M, D'Angelo P, Cecchetto G, Klersy C, Dall'Igna P, Federico A, Siracusa F, Alaggio R, Bernini G, Conte M, De Laurentis T, Di Cataldo A, Inserra A, Santoro N, Tamaro P, Indolfi P: Mature and immature teratomas: results of the first paediatric Italian study. Pediatr Surg Int; 2007 Apr;23(4):315-22
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Teratoma is the most common germ cell tumour in childhood; mature (MT) and immature teratomas (IT) are benign tumours, but if they recur, they can be in some cases malignant.
  • Clinical data, treatment and results were all analysed.
  • Chemotherapy (CT) with Vinblastine, D: -actinomycin and cyclophosphamide was indicated for extra-testicular IT grade 2 or 3.
  • MT was diagnosed in 127 patients (93 F and 34 M, age 1-192 months, median 24): 58 patients had gonadic tumour (23 testicular, 35 ovaric), 69 extragonadic (45 sacrococcygeal, 11 mediastinic, 7 retroperitoneal, 6 in other sites).
  • The T grading was 1 in 14 cases, 2 in 26, 3 in 16; 28 had gonadic T (17 ovary, 11 testis), 28 extragonadic (sacrococcygeal 19, mediastinic 3, retroperitoneal 2, other sites 4).
  • [MeSH-major] Ovarian Neoplasms / epidemiology. Teratoma / epidemiology. Testicular Neoplasms / epidemiology
  • [MeSH-minor] Age Distribution. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Incidence. Infant. Infant, Newborn. Italy / epidemiology. Male. Neoplasm Staging. Prospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):228-34 [9293455.001]
  • [Cites] J Pediatr Surg. 2001 Jan;36(1):12-7 [11150431.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2137-43 [10561269.001]
  • [Cites] Med Pediatr Oncol. 2003 Nov;41(5):417-25 [14515380.001]
  • [Cites] J Pediatr Surg. 1992 Aug;27(8):1075-8; discussion 1078-9 [1403540.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):620-4 [9053485.001]
  • [Cites] J Pediatr Surg. 1987 Mar;22(3):274-7 [3559872.001]
  • [Cites] Med Pediatr Oncol. 1998 Jul;31(1):8-15 [9607423.001]
  • [Cites] Ann Surg. 1965 Dec;162(6):1091-5, 1100 [5845591.001]
  • [Cites] Crit Rev Oncol Hematol. 1990;10(2):99-110 [2163259.001]
  • [Cites] J Pediatr Surg. 1998 Feb;33(2):171-6 [9498381.001]
  • [Cites] Cancer. 1989 May 1;63(9):1657-67 [2467734.001]
  • [Cites] Pediatr Blood Cancer. 2004 Feb;42(2):169-75 [14752882.001]
  • [Cites] Crit Rev Oncol Hematol. 1990;10(2):89-98 [1694438.001]
  • [Cites] Med Pediatr Oncol. 1993;21(6):395-401 [8390599.001]
  • [Cites] Am J Obstet Gynecol. 1999 Aug;181(2):353-8 [10454682.001]
  • [Cites] J Pediatr Surg. 1974 Jun;9(3):389-98 [4843993.001]
  • [Cites] Cancer. 1976 May;37(5):2359-72 [1260722.001]
  • [Cites] AJR Am J Roentgenol. 1981 Aug;137(2):395-8 [6789651.001]
  • (PMID = 17333214.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


35. Aydin GB, Ciftçi AO, Yalçin B, Akçören Z, Cağlar M, Senocak ME, Büyükpamukçu M: Paratesticular metastasis from Wilms tumor associated with a hydrocele. Pediatr Blood Cancer; 2006 Jul;47(1):97-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular metastasis from Wilms tumor associated with a hydrocele.
  • Metastatic sites other than the lungs, lymph nodes, and liver are unusual for Wilms tumor (WT).
  • We considered that tumor cells spread through the patent processus vaginalis and grew at paratesticular space in hydrocele.
  • One month after the end of 12 months of salvage chemotherapy and abdominal radiotherapy, the patient has no evidence of disease.
  • [MeSH-major] Genital Neoplasms, Male / secondary. Neoplasm Recurrence, Local / pathology. Testicular Hydrocele / etiology. Wilms Tumor / pathology
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Humans. Male. Orchiectomy. Testicular Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16049972.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


36. Ross JH, Rybicki L, Kay R: Clinical behavior and a contemporary management algorithm for prepubertal testis tumors: a summary of the Prepubertal Testis Tumor Registry. J Urol; 2002 Oct;168(4 Pt 2):1675-8; discussion 1678-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical behavior and a contemporary management algorithm for prepubertal testis tumors: a summary of the Prepubertal Testis Tumor Registry.
  • PURPOSE: The Prepubertal Testis Tumor Registry was established by the Urologic Section of the American Academy of Pediatrics in 1980 to record data on a large number of prepubertal testis tumors regarding presentation, treatment and outcome to define appropriate management better.
  • MATERIALS AND METHODS: Relevant data in the prepubertal testis tumor registry were tabulated and analyzed.
  • RESULTS: There were 395 prepubertal patients who had a primary testis tumor.
  • Of the patients with yolk sac tumor 80% presented with stage 1 disease and overall survival was excellent.
  • Of all patients with stromal tumors metastases developed in only 1.
  • CONCLUSIONS: We recommend initial excisional biopsy for all amenable prepubertal testis tumors, except those with an alpha-fetoprotein level that is clearly increased for patient age.
  • Patients with stage I yolk sac tumor should be monitored closely, and those with recurrent or metastatic yolk sac tumor should be treated with chemotherapy.
  • Retroperitoneal lymph node dissection is reserved for patients with recurrent retroperitoneal masses following chemotherapy.
  • Aggressive treatment of metastatic Sertoli cell or undifferentiated stromal tumors is warranted.
  • [MeSH-major] Registries / statistics & numerical data. Testicular Neoplasms / congenital
  • [MeSH-minor] Algorithms. Child. Child, Preschool. Combined Modality Therapy. Endodermal Sinus Tumor / congenital. Endodermal Sinus Tumor / mortality. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Humans. Infant. Male. Neoplasm Staging. Prognosis. Sertoli Cell Tumor / congenital. Sertoli Cell Tumor / mortality. Sertoli Cell Tumor / pathology. Sertoli Cell Tumor / therapy. Sex Cord-Gonadal Stromal Tumors / congenital. Sex Cord-Gonadal Stromal Tumors / mortality. Sex Cord-Gonadal Stromal Tumors / pathology. Sex Cord-Gonadal Stromal Tumors / therapy. Survival Rate. United States. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12352332.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


37. Ferrari A, Bisogno G, Casanova M, Meazza C, Piva L, Cecchetto G, Zanetti I, Pilz T, Mattke A, Treuner J, Carli M: Paratesticular rhabdomyosarcoma: report from the Italian and German Cooperative Group. J Clin Oncol; 2002 Jan 15;20(2):449-55
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: We report the experience of the German-Italian Cooperative Group with 216 pediatric patients with paratesticular rhabdomyosarcoma treated over 20 years.
  • Among the nonmetastatic patients, complete tumor resection was performed in 83% of cases.
  • All patients received chemotherapy, which was reduced in intensity and duration for patients with low-risk features in subsequent protocols.
  • RESULTS: Among 72 patients with a negative retroperitoneal computed tomography (CT) scan, surgical assessment detected nodal involvement in only one case.
  • Retroperitoneal nodal recurrence was the major cause of treatment failure.
  • Univariate analysis revealed the prognostic value of tumor invasiveness, size, and resectability, as well as of nodal involvement and age, in patients with localized tumor.
  • CONCLUSION: The outcome for patients with localized paratesticular rhabdomyosarcoma is excellent, despite the reduction in chemotherapy over the years: an alkylating agent-free and anthracycline-free regimen is adequate treatment for low-risk patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rhabdomyosarcoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. Lymphatic Metastasis. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11786573.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Lal DR, Su WT, Wolden SL, Loh KC, Modak S, La Quaglia MP: Results of multimodal treatment for desmoplastic small round cell tumors. J Pediatr Surg; 2005 Jan;40(1):251-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of multimodal treatment for desmoplastic small round cell tumors.
  • We examined the effects of multimodal therapy including induction chemotherapy, aggressive surgical debulking, and external beam radiotherapy on patients with DSRCT.
  • Data were collected on patient demographics, presenting symptoms, tumor location and extent, treatment regimen, and overall survival.
  • In 63 patients (96%), the primary tumor was located in the abdomen or pelvis.
  • Twenty-nine of these patients (44%) underwent induction chemotherapy (P6), surgical debulking, and radiotherapy.
  • Three-year survival was 55% in those receiving chemotherapy, surgery, and radiotherapy vs 27% when all 3 modalities were not used (P < .02).
  • Gross tumor resection was highly significant in prolonging overall survival; 3-year survival was 58% in patients treated with gross tumor resection compared to no survivors past 3 years in the nonresection cohort (P < .00001).
  • CONCLUSIONS: Multimodal therapy results in improved survival in patients with DSRCT.
  • [MeSH-major] Sarcoma, Small Cell / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Abdominal Neoplasms / therapy. Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Pelvic Neoplasms / pathology. Pelvic Neoplasms / surgery. Pelvic Neoplasms / therapy. Radiotherapy. Surgical Procedures, Operative. Survival Analysis. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery. Testicular Neoplasms / therapy. Thoracic Neoplasms / pathology. Thoracic Neoplasms / surgery. Thoracic Neoplasms / therapy. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868593.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


39. Göbel U, Calaminus G, Schneider DT, Schmidt P, Haas RJ, MAKEI and MAHO Study Groups of the German Society of Pediatric Oncology and Hematology, and the SIOP CNS GCT Study Group: Management of germ cell tumors in children: approaches to cure. Onkologie; 2002 Feb;25(1):14-22
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The introduction of cisplatinum chemotherapy and current advances in the surgical treatment have resulted in a dramatic improvement of the prognosis of children with malignant germ cell tumors (GCT).
  • Cisplatinum chemotherapy generally results in sufficient systemic tumor control, but local relapses may still occur in patients who did not receive adequate local treatment.
  • Therefore, the therapeutic consideration must take into account age, primary site of the tumor, and its histology.
  • In gonadal tumors, there is a high chance of primary complete resection since these tumors tend to be encapsulated, and particularly testicular GCT are often detected at a low tumor stage.
  • In these tumors, a neoadjuvant or preoperative chemotherapy after clinical diagnosis by imaging and evaluation of tumor markers significantly facilitates complete resection on delayed surgery.
  • In addition, the impact of chemotherapy on local tumor control may be enhanced by locoregional hyperthermia.
  • In intracranial GCT, radiotherapy significantly contributes to local tumor control, and doses are stratified according to histology.
  • These general considerations have been integrated into national and international cooperative treatment protocols.
  • In most current protocols, treatment is stratified according to an initial risk assessment that includes the parameters age, site, histology, stage, completeness of resection and the tumor markers alpha(1)-fetoprotein (AFP) and human choriogonadotropin (beta-HCG).
  • Moreover, the previously high-risk groups may now expect a favorable prognosis with this risk-adapted treatment, whereas an increasing number of low-risk patients are treated expectantly or with significantly reduced chemotherapy.
  • As current biologic studies reveal distinct genetic patterns in childhood GCT, it can be expected that further combined clinical and genetic studies will be valuable for risk assessment of childhood GCT.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Female. Humans. Infant. Infant, Newborn. Male. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger GmbH, Freiburg
  • (PMID = 11893878.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 66
  •  go-up   go-down


40. Hirayama Y, Kubota M, Imamura M, Imai C, Okuyama N, Tsukada M, Kobayashi K, Sato K, Takachi T, Iwavuchi H, Uchiyama M: A 2-year-old boy with a stage III yolk sac tumor occurring in an intra-abdominal retained testis. J Pediatr Surg; 2009 Dec;44(12):2395-8
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 2-year-old boy with a stage III yolk sac tumor occurring in an intra-abdominal retained testis.
  • We, herein, report the case of a 2-year-old boy who presented with a huge yolk sac tumor with retroperitoneal lymph nodes metastasis that originated in a left intra-abdominal undescended testis.
  • Computed tomography and magnetic resonance imaging showed a huge round tumor connecting to the left retroperitoneal lymph nodes with metastasis extending from the left pelvic region to the left renal hilum.
  • The right abdominal tumor appeared to be a giant testis that had strangulated at the neck of the cord.
  • The tumor had ruptured at the side of the left pelvic lymph node metastasis, and a yolk sac tumor was diagnosed from a histologic analysis of the resected specimens.
  • Postoperative PEB chemotherapy was effective, and a complete surgical resection of the tumor was performed 3 months after the initial laparotomy.
  • The pathologic findings showed fibrous tissue without any tumor cells.
  • This case might be a coincidental association of a yolk sac tumor occurring in an undescended testis, which thus caused a delay in making an accurate diagnosis.
  • [MeSH-major] Cryptorchidism / diagnosis. Endodermal Sinus Tumor / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] CA-125 Antigen / blood. Child, Preschool. Humans. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Male. Neoplasm Staging. Preoperative Care. Retroperitoneal Neoplasms / secondary. Testis / pathology. Testis / surgery. Tomography, X-Ray Computed. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20006035.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / alpha-Fetoproteins
  •  go-up   go-down


41. Derwich K, Wachowiaki J, Kaczmarek-Kanoldi M, Balcerska A, Balwierz W, Chybicka A, Kowalczyk JR, Matysiak M, Jackowska T, Sońta-Jakimczyk D, Wysocki M, Chełmecka-Hanuszewicz L, Cwiklińska M, Kołtan A, Malinowska I, Odój T, Płoszyńska A, Steczowicz M, Wojciechowska V, Wójtowicz A, Polish Pediatric Leukemia/Lymphoma Study Group: [Treatment results in children with the standard risk acute lymphoblastic leukemia treated with high dose of methotrexate (5.0 g/m2). 11 years of the Polish Pediatric Leukemia/Lymphoma Study Group experience]. Przegl Lek; 2006;63(1):7-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment results in children with the standard risk acute lymphoblastic leukemia treated with high dose of methotrexate (5.0 g/m2). 11 years of the Polish Pediatric Leukemia/Lymphoma Study Group experience].
  • Among them, 21 patients failed to respond to therapy: 2 (1.0%) early deaths, 2 (1.0%) deaths during I complete remission, 16 (8.2%) relapses, 1 (0.5%) second neoplasm.
  • Application of high dose of methotrexate is safety and effective in prevention of relapses, especially meningeal and testicular involvement.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Methotrexate / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Infant. Male. Poland / epidemiology. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16892891.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


42. Talon I, Moog R, Kauffmann I, Grandadam S, Becmeur F: Sertoli cell tumor of the testis in children: reevaluation of a rarely encountered tumor. J Pediatr Hematol Oncol; 2005 Sep;27(9):491-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli cell tumor of the testis in children: reevaluation of a rarely encountered tumor.
  • Testis tumors are uncommon in childhood, and they differ from adult tumors in terms of histology and frequency.
  • They are more frequently benign, but because of the absence of specific signs of malignancy, treatment consists of radical orchiectomy, sometimes followed by radiotherapy or chemotherapy based on histologic analysis.
  • In the authors' hospital, of 13 testis tumors diagnosed since 1996, only 2 were Sertoli cell tumors.
  • It would be helpful to have an algorithm for the management of testis tumors, outlining how to make the diagnosis of malignancy and which treatment and follow-up to pursue.
  • [MeSH-major] Algorithms. Sertoli Cell Tumor / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Age Factors. Child, Preschool. Humans. Infant. Male. Neoplasm Staging. Orchiectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16189443.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Lo Curto M, Lumia F, Alaggio R, Cecchetto G, Almasio P, Indolfi P, Siracusa F, Bagnulo S, De Bernardi B, De Laurentis T, Di Cataldo A, Tamaro P: Malignant germ cell tumors in childhood: results of the first Italian cooperative study "TCG 91". Med Pediatr Oncol; 2003 Nov;41(5):417-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant germ cell tumors in childhood: results of the first Italian cooperative study "TCG 91".
  • BACKGROUND AND AIMS: About 20% of patients with germ cell tumor (GCT) are still resistant to therapy.
  • The site of the primary tumor was gonadal in 59, extragonadal in 36.
  • The treatment was surgery alone in 31; surgery plus radiotherapy in 1; chemotherapy +/- surgery in 63.
  • Post-chemotherapy resection in 19 (10 complete, 9 partial).
  • The chemotherapy regimen was carboplatin 400 mg/m2/day on days 1, 2; etoposide 150 mg/m2/day on days 1, 2; ifosfamide 1,500 mg/m2/day on days 21, 22; dactinomycin 1.5 mg/m2/day on day 21; vincristine 1.5 mg/m2/day on day 21.
  • Three patients died because of toxicity and two non-responders (to primary chemotherapy), died of progression; among the remaining 90 patients 20 relapsed, 9 are in second remission, 2 are alive with disease, and 9 died of disease progression (one from progression and intracranial hemorrhage).
  • Survival according to: (a) site: testis: 100%; ovary: 88%; sacrococcyx: 69.6%; other sites: 33.3% (P < 0.001);.
  • All the pts who had complete resection of the primary tumor at diagnosis or at delayed surgery, remained in remission.
  • CONCLUSIONS: Multivariate analysis showed that the primary site of tumor was the only independent prognostic factor for survival and EFS.
  • [MeSH-major] Germinoma / pathology. Germinoma / therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Testicular Neoplasms / pathology. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Age Distribution. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. Confidence Intervals. Female. Humans. Incidence. Italy / epidemiology. Male. Multivariate Analysis. Neoplasm Staging. Probability. Prognosis. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 14515380.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


44. Segev DL, Ha TU, Tran TT, Kenneally M, Harkin P, Jung M, MacLaughlin DT, Donahoe PK, Maheswaran S: Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway. J Biol Chem; 2000 Sep 15;275(37):28371-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report, we demonstrate MIS type II receptor expression in normal breast tissue and in human breast cancer cell lines, breast fibroadenoma, and ductal adenocarcinomas.
  • MIS inhibited the growth of both estrogen receptor (ER)-positive T47D and ER-negative MDA-MB-231 breast cancer cell lines, suggesting a broader range of target tissues for MIS action.
  • Treatment of breast cancer cells with MIS activated the NFkappaB pathway and selectively up-regulated the immediate early gene IEX-1S, which, when overexpressed, inhibited breast cancer cell growth.
  • These results identify the NFkappaB-mediated signaling pathway and a target gene for MIS action and suggest a putative role for the MIS ligand and its downstream interactors in the treatment of ER-positive as well as negative breast cancers.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Breast Neoplasms / drug therapy. Glycoproteins. Growth Inhibitors / pharmacology. NF-kappa B / physiology. Neoplasm Proteins. Testicular Hormones / pharmacology
  • [MeSH-minor] Animals. Anti-Mullerian Hormone. Apoptosis Regulatory Proteins. COS Cells. Female. Humans. Immediate-Early Proteins / genetics. Membrane Glycoproteins / genetics. Membrane Proteins. Receptors, Estrogen / analysis. Receptors, Peptide / analysis. Receptors, Transforming Growth Factor beta. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10874041.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA17393; United States / NICHD NIH HHS / HD / HD32112
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Glycoproteins; 0 / Growth Inhibitors; 0 / IER3 protein, human; 0 / Immediate-Early Proteins; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Peptide; 0 / Receptors, Transforming Growth Factor beta; 0 / Testicular Hormones; 0 / anti-Mullerian hormone receptor; 80497-65-0 / Anti-Mullerian Hormone
  •  go-up   go-down


45. Robertson KA, Bullock HA, Xu Y, Tritt R, Zimmerman E, Ulbright TM, Foster RS, Einhorn LH, Kelley MR: Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res; 2001 Mar 1;61(5):2220-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a pilot study, we have examined Ape1/ref-1 expression by immunohistochemistry in sections of germ cell tumors (GCTs) from 10 patients with testicular cancer of various histologies including seminomas, yolk sac tumors, and malignant teratomas.
  • Ape1/ref-1 was expressed at relatively high levels in the tumor cells of nearly all sections.
  • We hypothesized that elevated expression of Ape1/ref-1 is responsible in part for the resistance to therapeutic agents.
  • (b) elevated expression of Ape1/ref-1 in testicular cancer cell lines results in resistance to certain therapeutic agents; and (c) Ape1/ref-1 expression in GCT cell lines determined by immunohistochemistry and repair activity assays parallels the level of protection from bleomycin.
  • We further hypothesize that elevated Ape1/ref-1 levels observed in human testicular cancer may be related to their relative resistance to therapy and may serve as a diagnostic marker for refractory disease.
  • [MeSH-minor] DNA Repair. DNA-(Apurinic or Apyrimidinic Site) Lyase. Deoxyribonuclease IV (Phage T4-Induced). Drug Resistance, Neoplasm. Gene Transfer Techniques. Humans. Retroviridae / genetics. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11280790.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA76643; United States / NINDS NIH HHS / NS / NS38506; United States / NCI NIH HHS / CA / R43 CA83507; etc
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 11056-06-7 / Bleomycin; EC 3.1.21.2 / Deoxyribonuclease IV (Phage T4-Induced); EC 4.2.- / Carbon-Oxygen Lyases; EC 4.2.99.18 / APEX1 protein, human; EC 4.2.99.18 / DNA-(Apurinic or Apyrimidinic Site) Lyase
  •  go-up   go-down






Advertisement